Wegovy 0.5mg for weight loss: what changes at this stage of treatment

Why does the 0.5mg dose exist rather than jumping straight to a higher one?

The Wegovy titration schedule is built around tolerability. Semaglutide slows gastric emptying and acts on appetite-regulating centres in the brain, and both of those effects can cause nausea, particularly in the early weeks. Starting at 0.25mg gives the gut time to adapt; 0.5mg continues that process at a modest increase in exposure.

Clinically, 0.5mg is not where significant weight loss is expected to occur for most people. The licensed maintenance dose for weight management is 2.4mg, and the trial evidence (including the STEP 1 study published in the New England Journal of Medicine) was built on that endpoint. The earlier titration steps are essentially a settling-in period, designed so that when patients reach higher doses they can tolerate them.

That said, some people do notice a reduction in appetite at 0.5mg. Portion sizes may feel different. The urge to snack may ease slightly. This is real, but it is background signal rather than the main event. The fuller effects build as doses increase over the following months, as your prescriber guides you through the schedule.

If you are curious how 0.5mg compares to the next step up, our 1mg dose page covers what changes at that point, including how appetite suppression tends to become more noticeable once you move to the 1mg stage of treatment.

What side effects tend to show up at 0.5mg, and how long do they last?

Moving from 0.25mg to 0.5mg is when some people meet Wegovy's GI profile for the first time in a meaningful way. Nausea is the most commonly reported effect, followed by loose stools, constipation, reflux, and occasionally vomiting. These effects tend to peak in the days after an injection and ease as the week progresses. For most people they settle within one to three weeks at the new dose.

Fatigue and headache can also occur. The NHS medicines page for semaglutide lists the full range of known effects and is worth reading before you start or change dose. It is the patient-level resource the prescriber will also point you to.

Staying well-hydrated matters more than usual during this period, particularly if nausea is suppressing your appetite for fluids as well as food. Eating smaller portions and avoiding very fatty or rich meals at injection time can help. None of this replaces advice from your own prescriber, who will know your specific history.

Severe or persistent stomach pain, especially if it radiates to your back, needs urgent medical attention regardless of which dose you are on. That is true throughout treatment, not only at 0.5mg. If anything about your side effects worries you, the right step is to contact your prescribing team rather than wait for the next scheduled review.

Who typically spends more time at 0.5mg, and who moves on quickly?

For the majority of people, 0.5mg lasts four weeks before the prescriber moves the dose to 1mg. That is the standard cadence. But titration is a clinical decision, not a calendar event. Some people tolerate the step-up well and move through on schedule; others find that staying at 0.5mg a little longer helps them avoid side effects that had been difficult at 0.25mg.

There is no clinical benefit to rushing through titration. Arriving at 2.4mg quickly matters far less than arriving there able to stay there. A prescriber who knows your case (your weight trend, your side-effect pattern, any medicines you are taking alongside semaglutide) is the person best placed to judge the pace. The Wegovy overview page sets out the full titration pathway and what each stage is for.

One thing worth flagging: if you are thinking about timing your prescription order around a busy patch, say a holiday week or a Monday start so you can monitor the first few days at home, that is worth mentioning during your consultation. It is a practical detail, and prescribers hear it regularly.

People who have previously been on semaglutide, or who are switching from another GLP-1 medicine, may have a different starting point. That is a case-by-case clinical call, and evidence of your previous treatment would be part of any review at our pharmacy.

Does 0.5mg produce meaningful weight loss on its own?

Honestly, not reliably. The STEP 1 trial (the pivotal study for Wegovy at 2.4mg) showed an average body-weight reduction of around 15% over 68 weeks, and those results were built on reaching and sustaining the full maintenance dose. At 0.5mg, which most people move through in a single month, the exposure to semaglutide is too brief and too low for that level of effect.

Some people do lose a small amount of weight during titration, partly because appetite begins to shift and partly because starting any structured programme often prompts better habits. But expecting the 0.5mg phase to deliver major results sets an unfair benchmark. The question worth asking is not how much this dose achieves alone, but whether it positions you well to reach and sustain the 2.4mg maintenance stage, and for those interested in where dose development may head next, our page on Novo's higher-dose Wegovy work in the EU gives useful context.

If you are looking at the broader picture of what Wegovy treatment costs and what is included in a private prescription, the treatment options page covers what a compliant, clinician-reviewed prescription includes and what to check for when comparing providers.

The weight-management results are a function of the full course of treatment, not any individual dose. Keeping that perspective during titration makes the journey easier to read.